Pulmonary hypertension (PH) is a complex, progressive condition characterized by high blood pressure in the lungs' arteries. Understanding its fundamentals is crucial for effective diagnosis and management.
PH results from various etiologies leading to increased pulmonary vascular resistance and, ultimately, right heart failure. The endothelial dysfunction and abnormal vascular response contribute to the pathogenesis of this disorder.
PH often presents non-specifically, making diagnosis challenging. Symptoms, usually related to right heart failure, include dyspnea, chest pain, and syncope. The physical examination may reveal signs such as a loud P2 component of the second heart sound, jugular venous distension, and peripheral edema.
The diagnosis of PH involves an array of tests, including echocardiography, right heart catheterization, and pulmonary function tests. Echocardiography serves as a useful screening tool, while right heart catheterization confirms the diagnosis.
Treatment aims to improve symptoms, slow disease progression, and enhance quality of life. Therapeutic options include lifestyle modifications, pharmacotherapy, and surgical interventions. Pharmacological treatment encompasses vasodilators, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors.
Given the complex nature of PH, a multidisciplinary approach is often beneficial. Collaboration between cardiologists, pulmonologists, rheumatologists, and other specialists can optimize patient outcomes.
In conclusion, a comprehensive understanding of PH's fundamentals is key to its effective management. By appreciating its pathophysiology, clinical presentation, diagnostic approach, treatment strategies, and the importance of multidisciplinary care, healthcare professionals can significantly improve patient outcomes in this challenging condition.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation